Tempus AI (TEM) to Release Quarterly Earnings on Tuesday

Tempus AI (NASDAQ:TEM) is anticipated to issue its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $362.5520 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:30 PM ET.

Tempus AI Stock Up 2.3%

NASDAQ TEM opened at $51.95 on Tuesday. Tempus AI has a fifty-two week low of $36.22 and a fifty-two week high of $104.32. The business has a fifty day moving average price of $63.72 and a two-hundred day moving average price of $73.62. The company has a debt-to-equity ratio of 2.45, a current ratio of 3.28 and a quick ratio of 3.12. The stock has a market capitalization of $9.24 billion, a PE ratio of -43.66 and a beta of 5.22.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on TEM shares. Canaccord Genuity Group decreased their target price on Tempus AI from $95.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, December 22nd. Piper Sandler reduced their price target on shares of Tempus AI from $105.00 to $80.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 11th. Morgan Stanley lifted their price target on shares of Tempus AI from $80.00 to $85.00 and gave the company an “overweight” rating in a report on Monday, December 1st. Needham & Company LLC increased their price objective on shares of Tempus AI from $70.00 to $100.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Finally, JPMorgan Chase & Co. cut their target price on shares of Tempus AI from $85.00 to $80.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. Six research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Tempus AI has an average rating of “Hold” and a consensus target price of $87.20.

Insider Activity

In other news, COO Ryan Fukushima sold 5,000 shares of the stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $64.26, for a total transaction of $321,300.00. Following the transaction, the chief operating officer owned 148,808 shares of the company’s stock, valued at $9,562,402.08. This represents a 3.25% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Andrew Polovin sold 12,874 shares of the business’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $75.00, for a total value of $965,550.00. Following the completion of the sale, the executive vice president directly owned 107,590 shares of the company’s stock, valued at $8,069,250. The trade was a 10.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 716,825 shares of company stock valued at $49,064,457. Corporate insiders own 26.27% of the company’s stock.

Institutional Trading of Tempus AI

Hedge funds have recently bought and sold shares of the business. ARK Investment Management LLC boosted its position in Tempus AI by 5.3% in the fourth quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock worth $446,275,000 after purchasing an additional 381,816 shares during the last quarter. State Street Corp raised its stake in shares of Tempus AI by 9.8% during the 4th quarter. State Street Corp now owns 1,616,338 shares of the company’s stock worth $95,445,000 after purchasing an additional 143,676 shares during the period. Voloridge Investment Management LLC boosted its holdings in shares of Tempus AI by 183.0% in the 3rd quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock worth $129,708,000 after buying an additional 1,039,176 shares during the last quarter. Franklin Resources Inc. grew its position in Tempus AI by 0.4% during the third quarter. Franklin Resources Inc. now owns 1,456,120 shares of the company’s stock valued at $117,523,000 after buying an additional 5,375 shares during the period. Finally, AQR Capital Management LLC increased its holdings in Tempus AI by 6.4% during the third quarter. AQR Capital Management LLC now owns 904,872 shares of the company’s stock worth $73,032,000 after buying an additional 54,692 shares during the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.